Opyl Limited announced that it has entered a Master Services Agreement (MSA) and signed contracts to provide clinical trial recruitment services valued at $145,000 to Bristol Myers Squibb (BMS), a leading global pharmaceutical company. The recruitment contracts are for clinical studies in psoriatic arthritis, involving 120 patients in total and is expected to be carried out over approximately six months. BMS selected Opyl for its innovative Opin.AI platform, a digital health research recruitment solution, that has a proven track record of swift and accurate participant recruitment, limiting the risk of clinical trial failures, with 80% of trials worldwide failing to recruit on time or on budget.

The expected recruitment revenues together with the MSA, which provides Opyl with approved and preferred supplier status allowing it to bid and secure additional international or local contracts with BMS, is considered to be material and a significant validation of the Opin offering. BMS has more than 50 compounds in development in over 35 disease areas globally. By using Opin, Opyl believes it can help BMS de-risk its clinical development programs, particularly across APAC as the platform supports multiple languages, including Chinese, Spanish and Korean.